P703 Comparative activity of moxifioxacin vs. trimethoprim-sulfamethoxazole, cloxacillin, linezolid, clindamycin, and ciprofioxacin against intracellular methicillin-sensitive and community-acquired methicillin-resistant S. aureus

emergence of resistance. We show that the activity of antibiotics may markedly differ when tested against extracellular and intracellular bacteria (AAC 2006, 50:841-851). In this context, we have examined the intraphagocytic activity of moxifloxacin (MXF, recently approved for skin and soft-tissues infections) in comparison to (i) antibiotics commonly used for the treatment of CAMRSA infections (trimethoprim-sulfamethoxazole [TMP-SMX], cloxacillin [CLX], linezolid [LNZ], clindamycin [CLI], and (ii) ciprofloxacin [CIP] against fully-sensitive S. aureus (MSSA) and the newly-emerging commynity-acquired methicillin-resistant S. aureus (CA-MRSA).